Private Equity & Venture Capital - Page 1 | TalkMarkets
All Posts > Content under Private Equity & Venture Capital
1 to 16 of 242 Posts
1 2 3 ... 16
EC The Most Precious Thing Is Patient Cash
Article By: Martin Hutchinson
Monday, April 24, 2017 1:29 PM EDT
The truly wealthy man is he who has liquidity in today’s market – and the patience to hold off investing until prices have collapsed and bargains abound.
In this article: BRK-A, DIS, AAPL
Read
The Reality Of VR/AR M&A
Article By: Tim Merel
Sunday, April 23, 2017 7:28 PM EDT
Despite Facebook’s blockbuster $3 billion Oculus acquisition in 2014, VR/AR has been too early stage for large scale mergers and acquisitions (M&A) so far. But that’s set to change in the next 18 months, so let’s look at what could drive M&A deals.
Read
Hedge Fund Performance Is (Still) Improving! Everyone (Still) Doesn’t Care
Article By: The Heisenberg Report
Saturday, April 22, 2017 4:00 PM EDT
The meteoric rise of ETFs has conspired with $13 trillion in central bank liquidity to all but relegate active management to the dustbin of history. You can’t expect people to pay exorbitant fees for you to underperform a benchmark.
Read
World Out Of Whack: An Absurd Unintended Consequence Of Abnormally Low Rates
Article By: Chris MacIntosh
Wednesday, April 19, 2017 3:23 PM EDT
By going to zero or negative interest rates, the true market price of risk isn’t just distorted, it’s largely completely unknown at this point.
Read
Billion Dollar Unicorns: Zoom Video Communications Enters The Club
Article By: Sramana Mitra
Tuesday, April 18, 2017 10:58 AM EDT
Zoom’s market penetration is strongest among tech companies, but it also claims to work with 88% of the top 200 universities. It has over 400 employees and 450,000 business customers including 5800 educational institutions.
Read
Does Market Sentiment Help Explain Momentum?
Article By: Alpha Architect
Monday, April 17, 2017 1:31 PM EDT
Academic literature has investigated the existence and performance of two different types of momentum. The first is called cross-sectional momentum, the second is time-series momentum, also referred to as “trend-following”.
Read
E A Lesson In Insolvency
Article By: Mark Borkowski
Sunday, April 16, 2017 9:00 AM EDT
If your company, a supplier, or customer is going bankrupt, it’s important to stay involved in the process.
Read
"This Is A Cash-Burning Machine" - Uber Opens Up Its Books, Shows Staggering Losses
Article By: Tyler Durden
Saturday, April 15, 2017 5:59 PM EDT
Uber opened up its books to Bloomberg, prompting one analyst to exclaim "this is a cash-burning machine." But, Uber, according to The Wall Street Journal's Unicorn tracking database, remains the most valuable private company in the world.
Read
Private Equity Masquerade
Article By: Bill Smead
Tuesday, April 4, 2017 5:56 PM EDT
It seems that more than eight years after financial Armageddon ended, investors are still wondering if another one may be just around the corner.
In this article: AMZN, GOOG, ALK, LEN, AMGN
Read
Sheelah Kolhatkar: Hedge Funds Are The Robber Barons Of Our Time
Podcast By: Adam Taggart
Sunday, April 2, 2017 5:04 PM EDT
Sheelah Kolhatkar, former hedge fund analyst and staff writer at the New Yorker, thinks hedge funds have enjoyed enormous unfair advantages for far too long.
Listen
E Quiet Life: Interview With Netanel Eyal, CEO & Co-Founder
Article By: Startup Watch
Tuesday, March 28, 2017 8:34 AM EDT
QuietLife Technologies develops and applies noise-cancellation technologies in new ways, specifically to the problem of snoring. It is raising its Series A of funding.
Read
Citi Ventures And RRE Invest $11 Million In Clarity Money
Article By: Zack Miller
Thursday, March 23, 2017 6:19 PM EDT
Citi Ventures and venture capital firm RRE Ventures made a major Series B investment in Clarity Money.
Read
Pfizer Mega Blockbuster Prevnar 13 Being Challenged By Upstart SutroVax
Article By: Lorimer Wilson
Tuesday, March 21, 2017 2:41 PM EDT
SutroVax has reeled in a whopping $64 million to get them well into human studies for a new vaccine that will challenge the Pfizer mega block buster Prevnar 13 for the heavyweight title in its field.
In this article: PFE
Read
BlackRock: Smart Beta Strategies Have Room For Growth
Article By: AllAboutAlpha
Sunday, March 5, 2017 7:28 PM EDT
A recent Columbia Business School research paper looks into the transaction costs associated with smart beta strategies in order to estimate the capacity of each strategy.
Read
Three Legs, Two Stools, One Winner
Article By: Andrew Gordon
Wednesday, March 1, 2017 3:11 PM EDT
How can part-time “amateur” crowdfunders with limited resources, time and crowdfunding experience compete with the deep-pocketed, well-connected, highly experienced, full-time “professional” venture capitalists?
Read
Week In Review: BioSense Signs $68 Million China Deal With Neovacs For Therapeutic Vaccine
Article By: ChinaBio® Today
Saturday, February 25, 2017 3:36 PM EDT
BioSense Global, a New Jersey-Suzhou biotech, signed a $68 million option agreement with France's Neovacs for China rights to a therapeutic vaccine aimed at lupus and dermatomyositis.
In this article: NBRV, ABBV, AZN
Read
1 to 16 of 242 Posts
1 2 3 ... 16